205 related articles for article (PubMed ID: 17606734)
1. A novel alphavirus vaccine encoding prostate-specific membrane antigen elicits potent cellular and humoral immune responses.
Durso RJ; Andjelic S; Gardner JP; Margitich DJ; Donovan GP; Arrigale RR; Wang X; Maughan MF; Talarico TL; Olmsted RA; Heston WD; Maddon PJ; Olson WC
Clin Cancer Res; 2007 Jul; 13(13):3999-4008. PubMed ID: 17606734
[TBL] [Abstract][Full Text] [Related]
2. A phase I dose escalation trial of vaccine replicon particles (VRP) expressing prostate-specific membrane antigen (PSMA) in subjects with prostate cancer.
Slovin SF; Kehoe M; Durso R; Fernandez C; Olson W; Gao JP; Israel R; Scher HI; Morris S
Vaccine; 2013 Jan; 31(6):943-9. PubMed ID: 23246260
[TBL] [Abstract][Full Text] [Related]
3. Identification of MHC class II-restricted T-cell epitopes in prostate-specific membrane antigen.
Schroers R; Shen L; Rollins L; Xiao Z; Sonderstrup G; Slawin K; Huang XF; Chen SY
Clin Cancer Res; 2003 Aug; 9(9):3260-71. PubMed ID: 12960111
[TBL] [Abstract][Full Text] [Related]
4. DNA fusion gene vaccines induce cytotoxic T-cell attack on naturally processed peptides of human prostate-specific membrane antigen.
Vittes GE; Harden EL; Ottensmeier CH; Rice J; Stevenson FK
Eur J Immunol; 2011 Aug; 41(8):2447-56. PubMed ID: 21604260
[TBL] [Abstract][Full Text] [Related]
5. Alphavirus replicon particles expressing TRP-2 provide potent therapeutic effect on melanoma through activation of humoral and cellular immunity.
Avogadri F; Merghoub T; Maughan MF; Hirschhorn-Cymerman D; Morris J; Ritter E; Olmsted R; Houghton AN; Wolchok JD
PLoS One; 2010 Sep; 5(9):. PubMed ID: 20844763
[TBL] [Abstract][Full Text] [Related]
6. Screening of HLA-A24-restricted epitope peptides from prostate-specific membrane antigen that induce specific antitumor cytotoxic T lymphocytes.
Horiguchi Y; Nukaya I; Okazawa K; Kawashima I; Fikes J; Sette A; Tachibana M; Takesako K; Murai M
Clin Cancer Res; 2002 Dec; 8(12):3885-92. PubMed ID: 12473604
[TBL] [Abstract][Full Text] [Related]
7. Prostate-related antigen-derived new peptides having the capacity of inducing prostate cancer-reactive CTLs in HLA-A2+ prostate cancer patients.
Harada M; Matsueda S; Yao A; Ogata R; Noguchi M; Itoh K
Oncol Rep; 2004 Sep; 12(3):601-7. PubMed ID: 15289844
[TBL] [Abstract][Full Text] [Related]
8. Dendritic cell based PSMA immunotherapy for prostate cancer using a CD40-targeted adenovirus vector.
Williams BJ; Bhatia S; Adams LK; Boling S; Carroll JL; Li XL; Rogers DL; Korokhov N; Kovesdi I; Pereboev AV; Curiel DT; Mathis JM
PLoS One; 2012; 7(10):e46981. PubMed ID: 23056548
[TBL] [Abstract][Full Text] [Related]
9. Effective targeting of prostate cancer by lymphocytes redirected by a PSMA × CD3 bispecific single-chain diabody.
Fortmüller K; Alt K; Gierschner D; Wolf P; Baum V; Freudenberg N; Wetterauer U; Elsässer-Beile U; Bühler P
Prostate; 2011 May; 71(6):588-96. PubMed ID: 20945402
[TBL] [Abstract][Full Text] [Related]
10. Human dendritic cells genetically engineered to express cytosolically retained fragment of prostate-specific membrane antigen prime cytotoxic T-cell responses to multiple epitopes.
Mincheff M; Zoubak S; Altankova I; Tchakarov S; Makogonenko Y; Botev C; Ignatova I; Dimitrov R; Madarzhieva K; Hammett M; Pomakov Y; Meryman H; Lissitchkov T
Cancer Gene Ther; 2003 Dec; 10(12):907-17. PubMed ID: 14712317
[TBL] [Abstract][Full Text] [Related]
11. Co-delivery of PSA and PSMA DNA vaccines with electroporation induces potent immune responses.
Ferraro B; Cisper NJ; Talbott KT; Philipson-Weiner L; Lucke CE; Khan AS; Sardesai NY; Weiner DB
Hum Vaccin; 2011; 7 Suppl():120-7. PubMed ID: 21266849
[TBL] [Abstract][Full Text] [Related]
12. Biochemical nature and mapping of PSMA epitopes recognized by human antibodies induced after immunization with gene-based vaccines.
Todorova K; Zoubak S; Mincheff M; Kyurkchiev S
Anticancer Res; 2005; 25(6C):4727-32. PubMed ID: 16334167
[TBL] [Abstract][Full Text] [Related]
13. Identification of a prostate-specific membrane antigen-derived peptide capable of eliciting both cellular and humoral immune responses in HLA-A24+ prostate cancer patients.
Kobayashi K; Noguchi M; Itoh K; Harada M
Cancer Sci; 2003 Jul; 94(7):622-7. PubMed ID: 12841872
[TBL] [Abstract][Full Text] [Related]
14. Comparison of two cancer vaccines targeting tyrosinase: plasmid DNA and recombinant alphavirus replicon particles.
Goldberg SM; Bartido SM; Gardner JP; Guevara-Patiño JA; Montgomery SC; Perales MA; Maughan MF; Dempsey J; Donovan GP; Olson WC; Houghton AN; Wolchok JD
Clin Cancer Res; 2005 Nov; 11(22):8114-21. PubMed ID: 16299244
[TBL] [Abstract][Full Text] [Related]
15. Anti-prostate specific membrane antigen designer T cells for prostate cancer therapy.
Ma Q; Safar M; Holmes E; Wang Y; Boynton AL; Junghans RP
Prostate; 2004 Sep; 61(1):12-25. PubMed ID: 15287090
[TBL] [Abstract][Full Text] [Related]
16. Development and preclinical evaluation of an alphavirus replicon vaccine for influenza.
Hubby B; Talarico T; Maughan M; Reap EA; Berglund P; Kamrud KI; Copp L; Lewis W; Cecil C; Norberg P; Wagner J; Watson A; Negri S; Burnett BK; Graham A; Smith JF; Chulay JD
Vaccine; 2007 Nov; 25(48):8180-9. PubMed ID: 17961878
[TBL] [Abstract][Full Text] [Related]
17. Humoral immune response in prostate cancer patients after immunization with gene-based vaccines that encode for a protein that is proteasomally degraded.
Todorova K; Ignatova I; Tchakarov S; Altankova I; Zoubak S; Kyurkchiev S; Mincheff M
Cancer Immun; 2005 Jan; 5():1. PubMed ID: 15641767
[TBL] [Abstract][Full Text] [Related]
18. An immunogenic and protective alphavirus replicon particle-based dengue vaccine overcomes maternal antibody interference in weanling mice.
White LJ; Parsons MM; Whitmore AC; Williams BM; de Silva A; Johnston RE
J Virol; 2007 Oct; 81(19):10329-39. PubMed ID: 17652394
[TBL] [Abstract][Full Text] [Related]
19. Inhibition of prostate-specific membrane antigen (PSMA)-positive tumor growth by vaccination with either full-length or the C-terminal end of PSMA.
Kuratsukuri K; Sone T; Wang CY; Nishisaka N; Jones RF; Haas GP
Int J Cancer; 2002 Nov; 102(3):244-9. PubMed ID: 12397643
[TBL] [Abstract][Full Text] [Related]
20. Efficient transfer of PSA and PSMA cDNAs into DCs generates antibody and T cell antitumor responses in vivo.
Medin JA; Liang SB; Hou JW; Kelley LS; Peace DJ; Fowler DH
Cancer Gene Ther; 2005 Jun; 12(6):540-51. PubMed ID: 15678150
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
